<unk>  (also known as<unk>  is defined as a lymphoid (immune cells) and/or plasmacytic proliferations (rapid increase) due to therapeutic immunosuppression after organ transplantation especially in the patients who are undergoing solid organ or allogeneic (donor) hematopoietic stem cell transplantation.<unk>  was first discovered by Denis Parsons Burkitt, an Irish physician, in 1965. According to World Health Organization (WHO) classification system,<unk>  may be classified into 4 subtypes: early hyperplastic lesions, polymorphic lesions, monomorphic lesions, and classic Hodgkin-type lymphomas. Patients with<unk>  may develop serious complications of transplantation with infectious mononucleosis-like lesions due to Epstein-Barr virus (EBV) or polyclonal polymorphic B-cell hyperplasia. In some cases, B-cells may undergo mutations which will render them malignant, giving rise to a lymphoma. The malignant cell clone can become the dominant proliferating cell type, leading to a group of B cell lymphomas occurring in immunosuppressed patients following organ transplant.<unk>  arises from germinal center or<unk> -germinal center B cells (B-PTLD), which are normally involved the production of antibodies  and durable memory B cells.<unk>  is very rare, and the prevalence of<unk>  remains unknown.<unk>  is more commonly observed among young patients. The medical treatment for<unk> , includes: immunosuppression, antiviral therapy, interferon alpha therapy, CD20 antibody therapy, and chemotherapy.
Post transplant lymphoproliferative disorder
Posttransplantation lymphoproliferative disorder
AIDS-related lymphoma
Chronic neutrophilic leukemia surgery
Splenic marginal zone lymphoma
Hodgkin's lymphoma
Nodal marginal zone lymphoma
HIV coinfection with tuberculosis